Beam Therapeutics Inc. BEAM

Rank #2162 · Nasdaq · $2.8B market cap

Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.

Score

31.1

P/E

-21.1

P/B

3.82

ROE

-18.1%

Op. Margin

-46.7%

Debt Ratio

50%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Weak

P/E -21.1x, P/B 3.82x. Ranks in the top 68% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -18.1%. Ranks in the top 84% of the universe.

Safety ★★★★☆

Good

Debt ratio 50%. Ranks in the top 24% of the universe.

Growth ★★★★★

Excellent

Revenue growth of 520.0% year over year. Ranks in the top 1% of the universe.

Growth is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	$0.0B	$-0.1B	$-0.1B	$-0.1B	-417522.2	-47
2021	$0.0B	$-0.1B	$-0.1B	$-0.1B	-417522.2	-176
2022	$0.0B	$-0.1B	$-0.2B	$-0.2B	-553166.7	-322
2023	$0.1B	$-0.4B	$-0.4B	$0.2B	-757.0	248
2024	$0.1B	$-0.3B	$-0.3B	$0.8B	-555.6	58
2025	$0.4B	$-0.2B	$-0.1B	$0.7B	-46.7	50